MedTrace Logo

Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients

NCT00290823 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2017-02-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether a short course of increased corticosteroid dosing with tapered dosing decreases seizure frequency as compared to standard corticosteroid dosing in patients with neurocysticercosis (NCC).

Conditions

  • Neurocysticercosis

Interventions

DRUG

Albendazole

400 mg tablet taken orally twice daily

DRUG

Dexamethasone

6mg or 8mg taken daily

DRUG

Omeprazole

20 mg tablet taken orally daily

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Theodore E. Nash, MD · Gastrointestinal Parasites Section, Laboratory of Parasitic Diseases, NIAID

  • Hector H. Garcia, MD, PhD · Department of Microbiology, Universidad Peruana Cayetano Heredia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Peru

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290823 on ClinicalTrials.gov